Items Tagged ‘Triple negative Breast Cancer (TNBC)’

June 9, 2017

Shows Improved Outcomes with Addition of Keytruda® in Triple Negative High-Risk Breast Cancer


The results from the I-SPY 2 TRIAL investigating Keyytruda (pembrolizumab), in combination with standard therapy as a pre-operative (neoadjuvant) treatment for patients with locally advanced breast cancer were released at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.  The estimated pathologic complete response (pCR) rate increased nearly threefold in patients with triple-negative […]

View full entry

Tags: Breast Cancer, checkpoint inhibitor, keytruda, News, opdivo, PD-1, precision medicine, Triple negative Breast Cancer (TNBC), Yervoy